HTBX Heat Biologics Inc.

0.37
-0.01  -2%
Previous Close 0.38
Open 0.39
Price To Book 0.57
Market Cap 12,740,928
Shares 34,066,652
Volume 62,854
Short Ratio
Av. Daily Volume 122,671
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 4Q 2019.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)